Europe HLA Typing for Transplant Market (2025-2030)
The Europe HLA Typing for Transplant Market was valued at $292.4 Million in 2025 and projected to reach to $380.2 Million by 2030, representing a compound annual growth rate of 5.4%. Europe's HLA typing for transplant market is positioned for steady growth driven by an aging population requiring organ transplants and stringent regulatory mandates across EU member states.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe HLA Typing for Transplant Market Trends and Insights
- In Europe, the demand for HLA typing services is driven by an aging population requiring organ transplants, advances in molecular typing technologies, and stringent regulatory frameworks that mandate comprehensive tissue matching.
- Europe's mature healthcare infrastructure and high transplant volumes across countries like Germany, France, Spain, and the United Kingdom support sustained market expansion through 2030. The European market benefits from established transplant networks, reimbursement policies favoring HLA testing, and increasing adoption of next-generation sequencing (NGS) platforms.
- In Europe, healthcare providers are investing in high-resolution typing methods to improve transplant outcomes and reduce rejection rates.
- The region's focus on precision medicine and standardized protocols positions Europe as a key growth market, with the forecast period (2025–2030) expected to see accelerated adoption of automated HLA typing solutions across transplant centers..
Key Market Statistics
- CAGR (2025-2030) 5.4% CAGR
- Market Size, 2025 ~USD 292.4 Million
- Forecast, 2030 ~USD 380.2 Million
- Geography Europe
Europe HLA Typing for Transplant Market Overview
Market Valuation & Growth :
Europe's HLA typing for transplant market is valued at $292.4 million in 2025, with a projected growth to $380.2 million by 2030, representing a steady CAGR of 5.4% over the forecast period.
Aging Population Demand :
Europe's aging demographic is driving increased demand for organ transplants and HLA typing services. The rising prevalence of end-stage organ diseases among elderly populations necessitates advanced tissue compatibility testing.
Regulatory Compliance Requirements :
Stringent European regulatory frameworks mandate comprehensive tissue typing and HLA compatibility assessments for all transplant procedures, ensuring high adoption rates of HLA typing technologies across member states.
Molecular Technology Advancement :
Advances in molecular HLA typing technologies, including next-generation sequencing and high-resolution testing methods, are enhancing accuracy and reducing turnaround times across European transplant centers.
Europe HLA Typing for Transplant Market Dynamics
- The region benefits from well-established healthcare infrastructure, high transplant volumes, and continuous investment in molecular diagnostics technology.
- Molecular typing methods are increasingly replacing traditional serological approaches, improving compatibility matching and transplant outcomes. The market outlook remains positive as European healthcare systems prioritize transplant efficiency and patient outcomes.
- Collaborations between transplant centers and diagnostic laboratories, coupled with reimbursement support from national health systems, will sustain market expansion.
- However, growth may be moderated by market saturation in developed nations and cost containment pressures within healthcare budgets..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Key Takeaways
- Europe's HLA typing market reaches $292.4M in 2025 and grows to $380.2M by 2030 at 5.4% CAGR.
- In Europe, NGS-based high-resolution typing is becoming the standard, replacing traditional serological methods.
- Europe's regulatory environment and reimbursement policies strongly support HLA testing adoption across transplant programs.
- In Europe, aging demographics and rising organ transplant demand drive sustained market growth through 2030.
HLA Typing for Transplant Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | INDEPENDENT REFERENCE LABORATORIES (End User) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 6% from 2025 to 2030 |
| Largest Segment | DIAGNOSTIC APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 1.05 (2025) |
| Revenue Forecast (Billions) | ~USD 1.4 (2030) |
| Segments Covered | Product & Service, Technology, Type, Application, Transplant Type, End User |
Europe HLA Typing for Transplant Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Consumables
- Software & Services
By Technology
- Molecular Assays
- Non-Molecular Assays
By Type
- Antibody Screening
- Chimerism Monitoring
- Next-Generation Sequencing
- Other Diagnostic Applications
- Other Pcr-Based Molecular Assays
- Other Sequencing-Based Molecular Assays
- Pcr-Based Molecular Assays
- Real-Time Pcr
- Sanger Sequencing
- Sequence-Specific Oligonucleotide-Pcr
- Sequence-Specific Primer-Pcr
- Sequencing-Based Molecular Assays
By Application
- Diagnostic Applications
- Research Applications
By Transplant Type
- Soft-Tissue Transplants
- Solid Organ Transplants
- Stem Cell Transplants
By End User
- Hospitals & Transplant Centers
- Independent Reference Laboratories
- Research Laboratories & Academic Institutes
EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS & TRANSPLANT CENTERS | 170.87 | 180.68 | 190.95 | 202.16 | 214.82 | 229.62 | 245.55 | 262.8 | 6.6 |
| INDEPENDENT REFERENCE LABORATORIES | 85.78 | 87.91 | 90 | 92.26 | 94.89 | 98.13 | 101.48 | 104.98 | 3.1 |
| RESEARCH LABORATORIES & ACADEMIC INSTITUTES | 11.12 | 11.27 | 11.41 | 11.55 | 11.72 | 11.95 | 12.18 | 12.39 | 1.7 |
| TOTAL | 267.76 | 279.86 | 292.35 | 305.97 | 321.43 | 339.71 | 359.21 | 380.17 | 5.4 |
Target Audience
- Diagnostic Laboratory Operators : Need market data to assess expansion opportunities, technology investments, and competitive positioning within European HLA typing services and transplant diagnostics.
- Medical Device & IVD Manufacturers : Require regional market insights to guide product development, regulatory strategy, and commercial launch planning for HLA typing platforms and reagents across Europe.
- Transplant Center Administrators : Seek market intelligence on technology trends, best practices, and benchmarking data to optimize HLA typing capabilities and improve transplant outcomes in their facilities.
- Healthcare Investors & Consultants : Need comprehensive market analysis and growth forecasts to evaluate investment opportunities, M&A targets, and strategic partnerships in the European transplant diagnostics sector.
- Healthcare Policy Makers : Require market data to inform reimbursement policies, regulatory frameworks, and healthcare resource allocation for HLA typing and organ transplant services across European nations.
Key Companies in the Europe HLA Typing for Transplant Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Instruments,Reagents,Software, |
| QUIDEL CORPORATION | United States | Public Company | Instruments (Transfusion & Molecular Platforms used in HLA/compatibility workflows),Reagents & Consumables (Antibody Screening, Donor Typing, Molecular Assays),Software & Informatics, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | PCR-based HLA typing (SSO, SSP, Real-time),NGS-based HLA typing,Sanger-based HLA typing, |
| ILLUMINA, INC. | United States | Public Company | NGS instruments,NGS reagents and consumables,Software and DRAGEN-based analysis, |
| QIAGEN | Netherlands | Public Company | Reagents & Assays (PCR, NGS, Sanger HLA, immune response),Instruments (PCR, NGS, sample prep, QC),Software & Bioinformatics (HLA typing, chimerism, data analysis), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Instruments (PCR, real-time, supporting platforms),Reagents & consumables for HLA typing and chimerism,Software & informatics for transplant workflows, |
| CAREDX, INC. | United States | Public Company | PCR-based HLA typing (SSO, SSP, Real-time),NGS-based HLA typing (AlloSeq Tx and related),Sanger-based HLA typing, |
| DIASORIN S.P.A. | Italy | Public Company | Reagents and assays (HLA-related and transplant-adjacent),Instruments and platforms (LIAISON, Simplexa, xMAP-based systems),Software and informatics for transplant workflows, |
| BECTON, DICKINSON AND COMPANY | United States | ||
| EUROBIO SCIENTIFIC | France | Public Company | Reagents (PCR, NGS, Sanger),Software (HLA typing, data analysis),Instruments and related hardware, |
KINDRED HEALTHCARE INC.
Kindred Healthcare Inc. is a large private healthcare services company founded in 1985 in the United States, employing 64,200 people. The company operates across multiple healthcare service segments.
QUIDEL CORPORATION
Quidel Corporation is a publicly traded diagnostic company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic testing solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large publicly traded life sciences company founded in 1956 in the United States with 125,000 employees. The company provides laboratory equipment, reagents, and analytical instruments globally.
ILLUMINA, INC.
Illumina, Inc. is a publicly traded genomics company founded in 1998 in the United States with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
QIAGEN
QIAGEN is a publicly traded molecular diagnostics company founded in 1984 in the Netherlands with 5,500 employees. The company provides sample and assay technologies for molecular testing.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a publicly traded life sciences company founded in 1952 in the United States with 7,450 employees. The company manufactures and distributes clinical diagnostic products and laboratory reagents.
CAREDX, INC.
CareDx, Inc. is a publicly traded molecular diagnostics company founded in 1998 in the United States with 763 employees. The company specializes in transplant diagnostics and precision medicine solutions.
DIASORIN S.P.A.
DiaSorin S.p.A. is a publicly traded Italian diagnostics company founded in 1968 with 3,242 employees. The company specializes in immunodiagnostic and molecular diagnostic products.
BECTON, DICKINSON AND COMPANY
Insufficient data provided for company description.
EUROBIO SCIENTIFIC
Eurobio Scientific is a publicly traded French diagnostics company founded in 1997 with 343 employees. The company develops and distributes in vitro diagnostic products.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 125.75 Million |
| UK | USD 133.66 Million |
| France | USD 96.09 Million |
| Spain | USD 11.8 Million |
| Italy | USD 8.35 Million |
| Rest Of Europe | USD 4.53 Million |
Country market size visualization
Reasons to Buy this Report
- Country-Level Market Insights : Access detailed market sizing and growth projections for major European markets including Germany, UK, France, Spain, and Italy, enabling targeted market entry and expansion strategies.
- Regulatory Landscape Analysis : Understand Europe's stringent regulatory requirements for HLA typing and tissue compatibility testing, critical for compliance and market positioning across EU member states.
- Technology Adoption Trends : Gain insights into the adoption of molecular HLA typing technologies versus traditional methods across European transplant centers, informing product development and commercialization strategies.
- Competitive Positioning : Benchmark your organization against regional competitors and identify market gaps in specific European countries with varying market maturity levels and growth opportunities.
- Strategic Growth Planning : Leverage 5-year forecast data and demographic trends to develop evidence-based expansion plans, partnership strategies, and investment decisions within the European transplant diagnostics sector.
Frequently asked questions
What is the market size of HLA typing for transplants in Europe in 2025?
In Europe, the HLA typing for transplant market is valued at $292.4 million in 2025.
What is the projected market size for HLA typing in Europe by 2030?
Europe's HLA typing market is forecast to reach $380.2 million by 2030.
What is the CAGR for Europe's HLA typing market from 2025 to 2030?
Europe's HLA typing market is expected to grow at a compound annual growth rate of 5.4% between 2025 and 2030.
Which countries drive the largest share of Europe's HLA typing market?
In Europe, major transplant centers in Germany, France, Spain, and the United Kingdom represent the largest market contributors due to high transplant volumes and advanced healthcare infrastructure.
What technologies are driving growth in Europe's HLA typing market?
In Europe, next-generation sequencing (NGS) platforms and automated high-resolution typing systems are the primary growth drivers, replacing traditional serological methods.
RESEARCH METHODOLOGY
This study analyzed market variables related to small and medium-sized businesses and major corporations to balance primary and secondary research for the human leukocyte antigen (HLA) typing for transplant market. The next phase involved conducting primary research with industry experts along the value chain to validate the findings, assumptions, and market sizing. Several methodologies were employed to estimate the overall market size, including both top-down and bottom-up approaches. This study focuses on key market segments, emerging trends, regulatory frameworks, and competitive environments. It also examines leading market players and their strategies within this sector. In conclusion, the total market size was determined using top-down and bottom-up approaches and data triangulation to arrive at the final figure. Ongoing primary research was conducted throughout the study to validate and test each hypothesis.
Secondary Research
During the study, secondary research utilized a variety of sources, including directories and databases such as Bloomberg Businessweek, D&B Hoovers, and Factiva. Additional materials included white papers, annual reports, SEC filings, and investor presentations. This research approach collects and generates data that offers comprehensive, technical, and market-focused insights into the HLA typing for transplant market. The data provides information on key players and market segmentation based on recent industry trends and significant market developments. Additionally, a database of leading industry figures was created through this secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the HLA typing for transplant market. The primary sources from the demand side include medical OEMs, CDMOs, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
*Others include distributors, suppliers, product managers, business development managers, marketing managers, and sales managers.
Note: Companies are categorized into tiers based on their total revenue. As of 2024, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, the global HLA typing for transplant market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the HLA typing for transplants business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and marketing executives.
Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:
- Generating a list of major global players/OEMs operating in the HLA typing for transplant market
- Mapping the annual revenue generated by major global players from the HLA typing segment (or the nearest reported business unit/product category)
- Revenue mapping of top players to cover at least ~75% of the global market share as of 2024
- Extrapolation of the revenue mapping of major players to derive the global value of the market
- Extrapolating the global value of the HLA typing for transplant market.
- Summation of market value for all segments and subsegments to achieve the actual value of the global HLA typing for transplant market
Data Triangulation
After arriving at the overall market size from the market size estimation process explained above, the global HLA typing for transplant market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, top-down and bottom-up approaches validated the HLA typing for transplant market.
Market Definition
HLA typing assays are critical in transplant immunology, as they facilitate the identification of HLA antigens essential for assessing donor-recipient compatibility and mitigating the risk of alloimmune rejection. These assays are pivotal in donor-recipient cross-matching, subject profiling, genotyping, and various diagnostic applications. Recent advancements in HLA typing technology, which enable high-resolution typing, afford precise delineation of HLA allele variations. This increased accuracy significantly enhances the predictive capability for transplant outcomes, thereby minimizing rejection and graft-versus-host disease incidence. As a result, these innovations are instrumental in making transplantation a more feasible and successful therapeutic option for patients.
Stakeholders
- Manufacturers of HLA typing products for transplant
- Distributors & suppliers of HLA typing products for transplant
- Hospitals, Transplant Centers, reference laboratories, Cord Blood Banks
- Research Laboratories and Academic Institutes
- Organ Procurement Organizations (OPOs)
- Non-government organizations
- Government regulatory authorities
- Contract manufacturers and third-party suppliers
- Clinical research organizations (CROs)
- Government and non-governmental regulatory authorities
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the HLA typing for transplant market based on product & service, technology, application, transplant type, end user, and region
- To provide detailed information regarding the major factors influencing the growth potential of the global HLA typing for transplant market (drivers, restraints, opportunities, challenges, and trends)
- To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global HLA typing for transplant market
- To provide an average selling price trend for the target product categories in HLA typing for transplant market
- To analyze key growth opportunities in the global HLA typing for transplant market for key stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), the Asia Pacific (Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
- To profile the key players in the global HLA typing for transplant market and comprehensively analyze their market shares and core competencies
- To track and analyze the competitive developments undertaken in the global HLA typing for transplant market, such as product launches, agreements, expansions, and acquisitions
Get the Full HLA Typing for Transplant Market Report
Full forecast, segment splits, and company analysis for all HLA Typing for Transplant Market.
- US HLA Typing for Transplant Market
- Canada HLA Typing for Transplant Market
- Germany HLA Typing for Transplant Market
- UK HLA Typing for Transplant Market
- France HLA Typing for Transplant Market
- Spain HLA Typing for Transplant Market
- Italy HLA Typing for Transplant Market
- China HLA Typing for Transplant Market
- India HLA Typing for Transplant Market
- Japan HLA Typing for Transplant Market
- Australia HLA Typing for Transplant Market
- South Korea HLA Typing for Transplant Market
- Brazil HLA Typing for Transplant Market
- Mexico HLA Typing for Transplant Market
- Rest Of Europe HLA Typing for Transplant Market
- Rest Of Asia Pacific HLA Typing for Transplant Market
- Rest Of Latin America HLA Typing for Transplant Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
